Your experience on this site will be improved by allowing cookies - see details Allow cookies Media Press releases Brochures Photos Videos Press Contact News Contact Country Websites ARGENTINA AUSTRALIA AUSTRIA BELGIUM BRAZIL CANADA CHILE CHINA COLOMBIA FRANCE GERMANY GREECE INDIA ITALY JAPAN KOREA, REPUBLIC OF MEXICO NETHERLANDS NORDIC POLAND PORTUGAL RUSSIA SOUTH AFRICA SPAIN SWITZERLAND TAIWAN UNITED KINGDOM UNITED STATES VENEZUELA Dermatology Resources DermQuest Derm101 About Galderma Focus on the Skin Medical Solutions Dermatology Innovations Corporate Responsibility Galderma Talents GALDERMA About Galderma Our Ambition Galderma at a Glance Worldwide presence R&D Locations Company History Newsroom Focus on the Skin Our interface with the world Skin structure Aging skin Dry skin Acne Atopic dermatitis Psoriasis Scalp psoriasis Onychomycosis Pigmentation disorders Rosacea Seborrheic Dermatitis Skin Cancer Other Conditions Medical Solutions Major Brands Azzalure Benzac Cetaphil Clobex Daylong Differin Epiduo Excipial Loceryl Metrogel Metvix Mirvaso Oracea Pliaglis Qilib Restylane Rozex Silkis Soolantra Tri-Luma All Products By name By condition Dermatology Innovations Research & Development Drug discovery Global development Manufacturing Partnerships Why Partner with Galderma Areas of Interest Corporate Responsibility President's letter Social responsibility & Education Funding Request Ethics & Values Supplier Code Sustainable development Galderma Talents Working at Galderma Job Areas Insider's View Job Opportunities Media Press releases Brochures Photos Videos Press Contact News Contact Expand GALDERMA Committed to the future of Dermatology Read more ... Talent Working at GaldermaRead more ... FOCUSED Patients at the heart of everything we doRead more ... PARTNER With Healthcare Professionals around the WorldRead more ... You are here » Home Search Medical solutions for the skin, our interface with the world. LATEST NEWS Saturday, September 16, 2017 ‘CLEAR’ (IGA 0) Rosacea Patients Experience a Delayed Time to Relapse Monday, September 11, 2017 Combined Use of Rosacea Therapies Ivermectin 1% cream and Brimonidine 0.33% gel Evaluated in MOSAIC Study Tuesday, July 25, 2017 Galderma Announces Enrollment of First Patient in Phase IIb Nemolizumab Trial in Atopic Dermatitis Ethically engaged to skin research Values, ethics and compliance are part of dermatology company Galderma’s culture More about ethics and values A unique capability in dermatological R&D Skin disease specialist Galderma has research and development facilities spread across different continents, including the world’s largest center dedicated to dermatology only More about research & development Serving professionals and patients By providing innovative medical solutions in order to help healthcare professionals best answer their patients’ needs More about medical dermatology solutions Join Galderma to achieve your potential Dermatology company Galderma recognizes the importance of attracting and retaining highest performing and talented employees from around the world More about Galderma talent Focus The 2017 SkinPact Awards Programme was launched at the Asian Dermatology Congress Galderma continues its mission of recognizing initiatives by dermatology organizations to improve skin health in their communities. In 2017 project submissions are open to dermatologists from Asia Pacific until 15 February 2017. > Read More and apply Discover the Cetaphil range of products Cetaphil products are recommended by more dermatologists than any other brand of skin cleansers and moisturizers. After all, they’ve been carefully formulated to provide effective, gentle skin care to help your skin look and feel its best — no matter what category your skin type falls into… Read more FOCUS ON THE SKIN Rosacea is a common, chronic inflammatory disorder skin disease. Fair-skinned individuals and women tend to be prone to it. Both genetic and environmental factors may be involved in the pathogenesis, but research has yet to reveal its exact causes… Read more. VIDEOS See all videos CORPORATE SOCIAL RESPONSIBILITY Skin disease specialists Galderma wishes to foster the future of dermatology through building and sustaining a strong and long-lasting community, bringing together patients and healthcare professionals with whom we work. “Our Giving” is a testimony of some of the positive initiatives we are involved in across the world More about our Corporate Social Responsibility Follow us on LinkedIn on Twitter Contact Galderma S.A. Avenue Gratta-Paille 2 CH - 1018 Lausanne Switzerland Galderma Websites Country Websites ARGENTINA AUSTRALIA BELGIUM BRAZIL CANADA CHILE CHINA COLOMBIA FRANCE GERMANY GREECE INDIA ITALY JAPAN KOREA, REPUBLIC OF MEXICO NETHERLANDS NORDIC POLAND PORTUGAL RUSSIA SOUTH AFRICA SPAIN SWITZERLAND TAIWAN UNITED KINGDOM UNITED STATES Dermatology Resources DermQuest Derm101 Contact us SiteMap Legal statement Privacy policy